Suppr超能文献

慢性淋巴细胞白血病(CLL)中的 Richter 转化——德国 CLL 研究组(GCLLSG)一线治疗试验的汇总分析。

Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials.

机构信息

Department I of Internal Medicine and Center of Integrated Oncology Aachen, University of Cologne, Bonn, Cologne, Duesseldorf, Cologne, Germany.

Department of Hematology and Oncology, Evangelisches Krankenhaus Hamm, Hamm, Germany.

出版信息

Leukemia. 2021 Jan;35(1):169-176. doi: 10.1038/s41375-020-0797-x. Epub 2020 Mar 17.

Abstract

Richter transformation (RT) is defined as development of aggressive lymphoma in patients (pts) with CLL. The incidence rates of RT among pts with CLL range from 2 to 10%. The aim of this analysis is to report the frequency, characteristics and outcomes of pts with RT enrolled in trials of the GCLLSG. A total of 2975 pts with advanced CLL were reviewed for incidence of RT. Clinical, laboratory, and genetic data were pooled. Time-to-event data, starting from time of CLL diagnosis, of first-line therapy or of RT diagnosis, were analyzed by Kaplan-Meier methodology. One hundred and three pts developed RT (3%): 95 pts diffuse large B-cell lymphoma (92%) and eight pts Hodgkin lymphoma (8%). Median observation time was 53 months (interquartile range 38.1-69.5). Median OS from initial CLL diagnosis for pts without RT was 167 months vs 71 months for pts with RT (HR 2.64, CI 2.09-3.33). Median OS after diagnosis of RT was 9 months. Forty-seven pts (46%) received CHOP-like regimens for RT treatment. Three pts subsequently underwent allogeneic and two pts autologous stem cell transplantation. Our findings show that within a large cohort of GCLLSG trial participants, 3% of the pts developed RT after receiving first-line chemo- or chemoimmunotherapy. This dataset confirms the ongoing poor prognosis and high mortality associated with RT.

摘要

里希特转化(RT)定义为慢性淋巴细胞白血病(CLL)患者中侵袭性淋巴瘤的发展。CLL 患者中 RT 的发生率范围为 2%至 10%。本分析的目的是报告 GCLLSG 试验中纳入的 RT 患者的频率、特征和结局。对 2975 例晚期 CLL 患者进行了 RT 发生率的回顾性分析。汇总了临床、实验室和遗传学数据。从 CLL 诊断、一线治疗或 RT 诊断开始,采用 Kaplan-Meier 方法分析时间事件数据。103 例患者发生 RT(3%):95 例弥漫性大 B 细胞淋巴瘤(92%)和 8 例霍奇金淋巴瘤(8%)。中位观察时间为 53 个月(四分位距 38.1-69.5)。无 RT 患者从初始 CLL 诊断到 OS 的中位时间为 167 个月,而 RT 患者为 71 个月(HR 2.64,95%CI 2.09-3.33)。RT 诊断后的中位 OS 为 9 个月。47 例(46%)患者接受 CHOP 样方案治疗 RT。3 例患者随后接受了异基因和 2 例自体干细胞移植。我们的研究结果表明,在 GCLLSG 试验参与者的大型队列中,3%的患者在接受一线化疗或化疗免疫治疗后发生 RT。该数据集证实了 RT 相关的持续不良预后和高死亡率。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验